Potent inhibitor of the tyrosine kinases c-Src, fibroblast growth factor receptor 1 (FGFR1), and platelet-derived growth factor receptor β
values are 8.4, 39.3 and 98.3 nM respectively). Also inhibits the checkpoint kinases Wee1 and Myt1; abolishes Cdc2 phosphorylation in numerous tumor cell lines and abrogates the G2
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from Pfizer Inc.
In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor.
Panek et al.
Radiosensitization of p53 mutant cells by PD0166285, a novel G2 checkpoint abrogator.
Wang et al.
Cancer Res., 2001;61:8211
Cell cycle regulation by the Wee1 inhibitor PD0166285, Pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line.
Hashimoto et al.
BMC Cancer, 2006;6:292
The citations listed below are publications that use Tocris products. Selected citations for PD 166285 dihydrochloride include:
Showing Results 1 - 1 of 1